TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company
integrating its novel delivery technology with immunotherapy to
transform treatment for patients with liver and pancreatic tumors,
announced today that the Company will present data from recent
research findings at the 2024 Society of Interventional Radiology
(SIR) Annual Scientific Meeting, to be held March 23-28, 2024, in
Salt Lake City, Utah.
TriSalus will share data on the technical feasibility and safety
of Pressure-Enabled Drug Delivery™ (PEDD) procedures in
hypovascular tumors and initial data regarding our Pancreatic
infusion technology, which is currently 510(k) cleared by the U.S.
Food and Drug Administration (FDA) and in the Phase 1 clinical
trial with nelitolimod in locally advanced pancreatic cancer.
The TriSalus approach seeks to address many of the key
challenges associated with delivering therapeutics to pancreas
tumors. In contrast to the liver, pancreas arteries feeding tumors
are difficult to access and venous access affords anatomic
advantages. Additionally, pancreatic tumors exhibit a dense,
desmoplastic stroma that limits the delivery of therapeutics. The
technology is designed to address these mechanical barriers and
challenges by modulating pressure and flow, incorporating real-time
pressure sensing capability to optimize safety and delivery.
“The presentations featuring our PEDD approach illustrates that
TriSalus is committed to and focused on transforming how
therapeutics are delivered into biologically challenging liver and
pancreas tumors. Mechanical barriers present in the tumor
microenvironment, including high intra-tumoral pressure, may limit
the performance of many therapeutic classes including embolics and
immunotherapy. We look forward to our continued partnership with
the interventional radiology community to improve outcomes in a
variety of solid tumor indications,” noted Steven C. Katz, MD,
FACS, Chief Medical Officer.
Presentation details for SIR 2024 are as follows:
Presentation: Clinical Efficacy of
Pressure-Enabled Transarterial Embolization of Hypovascular,
Treatment-Refractory Metastases. Presenting Author: Koustav
Pal, MBBS, Postdoctoral Research Fellow at University of Texas MD
Anderson Cancer Center Date: Sunday, March 24, 2024
Time: 3:54 p.m. MT Location: Salt Lake Palace
Convention Center, Room 255C
Presentation: The PERIO-03 Trial:
Technical Feasibility and Safety of a Novel Pancreatic Retrograde
Venous Immunotherapy Infusion Intervention for Locally Advanced
Pancreatic Ductal Adenocarcinoma. Presenting Author: Rahul
A. Sheth, MD, Associate Professor at University of Texas MD
Anderson Cancer Center Date: Sunday, March 24, 2024
Time: 4:21 p.m. MT Location: Salt Lake Palace
Convention Center, Room 255B
The presentations will be available on the publications page of
the TriSalus website following the respective sessions.
About TriSalus Life Sciences
TriSalus Life Sciences is an oncology company integrating novel
delivery technology with immunotherapy to transform treatment for
patients with liver and pancreatic tumors.
The Company’s platform includes devices that utilize a
proprietary drug delivery technology and a clinical-stage
investigational immunotherapy. The Company’s two FDA-cleared
devices that deliver a range of therapeutics, using its proprietary
Pressure-Enabled Drug Delivery™ (PEDD™) approach: the TriNav®
Infusion System for hepatic arterial infusion of liver tumors and
the Pancreatic Retrograde Venous Infusion System for pancreatic
tumors. PEDD is a novel delivery approach designed to address the
anatomic limitations of arterial infusion to the pancreas. The PEDD
approach modulates pressure and flow in a manner that delivers more
therapeutic to the tumor and is designed to reduce undesired
delivery to normal tissue, bringing the potential to improve
patient outcomes. Nelitolimod (SD-101), the Company’s
investigational immunotherapeutic candidate, is designed to improve
patient outcomes by treating the immunosuppressive environment
created by many tumors, which can make current immunotherapies
ineffective in the liver and pancreas. Patient data generated
during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical
trials support the hypothesis that SD-101 delivered via PEDD may
have favorable immune effects within the liver and systemically.
The target for SD-101, TLR9, is expressed across cancer types and
the mechanical barriers addressed by PEDD are commonly present as
well. Nelitolimod delivered by PEDD will be studied across several
indications in an effort to address immune dysfunction and overcome
drug delivery barriers in the liver and pancreas.
In partnership with leading cancer centers across the country –
and by leveraging deep immuno-oncology expertise and inventive
technology development – TriSalus is committed to advancing
innovation that improves outcomes for patients. Learn more at
trisaluslifesci.com and follow us on X (formerly Twitter) and
LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements other than statements of historical facts
contained in this report, including statements regarding the
Company’s expected financial results for the three months ended
December 31, 2023 and the full year ended December 31, 2023, the
Company’s belief as to the factors causing the financial results,
and the Company’s projected operating runway into the second
quarter of 2024, are all forward-looking statements. In some cases,
you can identify forward-looking statements by terminology such as
“expect,” “may,” “potential,” “should,” “will,” “would” and other
similar expressions that are predictions of or indicate future
events and future trends, or the negative of these terms or other
comparable terminology.
The Company has based these forward-looking statements largely
on its current expectations and projections about future events and
financial trends that the Company believes may affect its financial
condition, results of operations, business strategy and financial
needs. These forward-looking statements are subject to a number of
known and unknown risks, uncertainties and assumptions, including,
but not limited to, the risk that our reported financial results
will differ from the estimates provided in this press release, the
Company’s ability to achieve its projected growth or maintain its
current levels of revenue, the Company’s ability to obtain
additional liquidity, the Company’s ability to continue as a going
concern, and other risk factors described in the Company’s filings
with the Securities and Exchange Commission, including the section
titled “Risk Factors”. See the Company’s Quarterly Report on Form
10-Q for the quarter ended September 30, 2023, filed with the SEC
on November 14, 2023 and other filings made with the SEC for a
discussion of important factors that may cause the Company’s actual
results to differ materially from those expressed or implied by the
Company’s forward looking statements. Moreover, the Company
operates in a very competitive and rapidly changing environment.
New risk factors emerge from time to time, and it is not possible
for the Company’s management to predict all risk factors nor can
the Company assess the impact of all factors on its business or the
extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in, or
implied by, any forward-looking statements.
In light of the significant uncertainties in these
forward-looking statements, you should not rely upon
forward-looking statements as predictions of future events.
Furthermore, if the Company’s forward-looking statements prove to
be inaccurate, the inaccuracy may be material. Except as required
by law, the Company undertakes no obligation to publicly update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240321258631/en/
For Media and Investor Inquiries: Argot Partners
212.600.1902 TriSalus@argotpartners.com
Grafico Azioni TriSalus Life Sciences (NASDAQ:TLSI)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni TriSalus Life Sciences (NASDAQ:TLSI)
Storico
Da Feb 2024 a Feb 2025
